Elevance Health stock snapshot and recent moves

Elevance Health (ELV) has been trading around US$319.36, with a return of about 9.6% over the past month but a return of roughly 13% decline over the past 3 months.

Short term share price momentum has picked up, with a 1 month share price return of 9.6%. However, this follows a 3 month share price return decline of 13% and a 1 year total shareholder return decline of 19.8%, which suggests sentiment has cooled compared to the longer term.

If Elevance Health has you reassessing healthcare exposure, it can be useful to see how other medical names are being priced and where growth stories are emerging through 35 healthcare AI stocks

With Elevance Health trading around US$319.36, an intrinsic discount flag of 0.683856 and an 18.5% gap to the average analyst price target, the real question is whether this signals a genuine value gap or a market already pricing in future growth?

Most Popular Narrative: 18.2% Undervalued

Against a last close of $319.36, the most followed narrative on Elevance Health points to a fair value of $390.54, implying a clear valuation gap in the model being used.

Elevance Health’s investment potential over the next 1-3 years lies in balancing risks associated with Medicaid declines, cost management, and regulatory uncertainties against growth opportunities in Medicare Advantage, value-based care, and digital health innovation. Its established market position and diversified portfolio provide resilience, but operational cost pressures and policy changes will be critical factors influencing performance.

Curious what justifies a higher fair value than today’s share price, according to NateF’s narrative? The explanation focuses on revenue mix, margin rebuilding, and the treatment of future cash flows in the model.

Result: Fair Value of $390.54 (UNDERVALUED)

However, the narrative can quickly break if Medicaid pressures or persistent medical cost inflation hit margins harder than expected and keep returns under pressure for longer.

Next Steps

With sentiment on Elevance Health divided between potential valuation upside and clear execution risks, it pays to check the numbers yourself and move quickly to shape your own view through 4 key rewards

Looking for more investment ideas?

If Elevance Health has sharpened your focus, do not stop here; widen your watchlist with ideas that match your risk, income, and quality preferences.

• Target higher income potential by scanning companies with resilient payouts and yields through 13 dividend fortresses.
• Spot quality at a discount by filtering for companies that combine solid fundamentals with attractive pricing using 63 high quality undervalued stocks.
• Prioritise peace of mind by zeroing in on companies that score well on stability and resilience via 72 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.